Skip to main content

Abatacept News

Therapeutic Intervention Feasible for Preventing Rheumatoid Arthritis in Patients at Risk

FRIDAY, Feb. 23, 2024 – Therapeutic intervention with abatacept is feasible for patients at risk for rheumatoid arthritis, according to a study published online Feb. 13 in The Lancet. Andrew P....

Drug Used to Treat Rheumatoid Arthritis May Also Help Prevent It

THURSDAY, Feb. 15, 2024 – Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website – FootballMatcher.com – to help people connect for pickup games. The fun wen...

U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)

PRINCETON, N.J.--(BUSINESS WIRE) December 15, 2021 – Bristol Myers Squibb (NYSE:BMY) today announced that Orencia (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the p...

Bristol-Myers Squibb’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults...

U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis

PRINCETON, N.J.--(BUSINESS WIRE)--Jul 30, 2011 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) formulation of Orencia...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Rheumatoid Arthritis, Psoriatic Arthritis

Abatacept patient information at Drugs.com